Sentinel lymph node status is the strongest independent predictor for disease free and overall survival in patients with thick melanoma

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 11, 2013, Pages 1454-1456

  Gambichler, T ^a   Scholl, L ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; THORAX RADIOGRAPHY; TUMOR THICKNESS; TUMOR VOLUME;

FEMALE; HUMANS; MALE; MELANOMA; SENTINEL LYMPH NODE BIOPSY;

EID: 84885949457     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12087     Document Type: Letter

References (10)

1. Rondelli F, Vedovati MC, Becattini C, et al,. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol Venereol 2012; 26: 560-565. doi: 10.1111/j.1468-3083.2011.04109.x. Epub 2011 May 11.
2. Wong SL, Balch CM, Hurley P, et al,., American Society of Clinical Oncology; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012; 30: 2912-2918.
3. Perrott RE, Glass LF, Reintgen DS, Fenske NA,. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003; 49: 567-588.
4. Jacobs IA, Chang CK, Salti GI,. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg 2004; 70: 59-62.
5. Cherpelis BS, Haddad F, Messina J, et al,. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001; 44: 762-766.
6. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL,. Prognostic implications of thick (≥ 4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002; 9: 754-761.
7. Gajdos C, Griffith KA, Wong SL, et al,. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer 2009; 115: 5752-5760.
8. Fujisawa Y, Otsuka F, Japanese Melanoma Study Group. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients. Melanoma Res. 2012; 22: 362-367.
9. Hinz T, Ahmadzadehfar H, Wierzbicki A, et al,. Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness > 4.00 mm): outcome analysis from a single institution. Eur J Nucl Med Mol Imaging 2012; 39: 1316-1325.
10. Göppner D, Ulrich J, Pokrywka A, Peters B, Gollnick H, Leverkus M,. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4.0 mm. Dermatology 2011; 222: 59-66.